ZYME — Zymeworks Inc.

Zymeworks Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $106 million for 2025, up from $76.3 million in 2024, driven by clinical and regulatory milestones and collaboration exercises.
• Operating Expenses: $198.5 million, down from $213.4 million in 2024, primarily due to a nonrecurring impairment charge in 2024.
• Net Loss: $81.1 million for 2025, improved from a net loss of $122.7 million in 2024.
• Cash Position: $270.6 million as of December 31, 2025, down from $324.2 million in 2024. The company expects its cash runway to extend beyond 2028, supported by anticipated milestone payments and a new financing agreement.
• Share Repurchase Program: Approximately $62.5 million utilized out of a $125 million program authorized in November 2025.

2. Strategic Updates and Business Highlights

• Zanidatumab Progress: Positive results from the Phase III HORIZON-GEA-01 trial, showing median progression-free survival (PFS) exceeding one year and overall survival (OS) exceeding two years in HER2-positive gastric cancer. The drug has received Breakthrough Therapy designation and is expected to be submitted for regulatory approval in 2026.
• Royalty Financing: A $250 million nonrecourse royalty-backed note financing with Royalty Pharma was announced, allowing Zymeworks to secure capital while retaining 70% of zanidatumab royalties.
• Clinical Trials: Ongoing Phase I trial for ZW251, with strong enrollment and plans for future updates. ZW191 is also progressing well, with data expected soon.
• Acquisition Strategy: The company is open to acquiring assets that align with its strategic goals, particularly in oncology and immunology, while maintaining a disciplined approach to capital allocation.

3. Forward Guidance and Outlook

• Operating Expenses: Expected to decrease by approximately 20% in 2026 compared to 2025, excluding acquisition-related expenses.
• Regulatory Milestones: Anticipated milestone payments of up to $440 million related to zanidatumab approvals in various regions, contributing to the cash runway.
• Future Catalysts: Plans to continue advancing clinical studies for ZW191 and ZW251, with IND submissions for multispecific programs expected in 2026.

4. Bad News, Challenges, or Points of Concern

• Cash Decrease: The cash position has declined year-over-year, raising concerns about liquidity, although the company maintains a strong runway.
• Competitive Pressures: The ADC (antibody-drug conjugate) space is becoming increasingly crowded, particularly with DLL3-targeting therapies, which may impact Zymeworks' ability to differentiate its products.
• Regulatory Risks: The timing and outcomes of regulatory submissions and approvals for zanidatumab and other assets remain uncertain, which could affect future revenue streams.

5. Notable Q&A Insights

• ZW251 Enrollment: The Phase I trial for ZW251 is progressing well, with expectations for a similar cadence to ZW191. The company is cautious about providing specific timelines for data releases.
• Royalty Financing Rationale: The timing of the royalty-backed financing was influenced by the current commercialization cycle of zanidatumab and the favorable cost of capital available.
• Future Acquisitions: The company is looking at a variety of assets for potential acquisition, emphasizing the importance of strategic fit and return on investment.
• Payload Resistance: The company is aware of challenges related to payload resistance in ADCs and is actively exploring next-generation payloads to address this issue.

This earnings call highlighted Zymeworks' strong progress in clinical development and strategic initiatives while also acknowledging the challenges and competitive landscape within the biotechnology sector.